Lupus
Laurent ARNAUD Lupusreference
3 years ago
✅ Probably one of my most important slides ⬇️
WHY IS MY #TREATMENT NOT WORKING (or not working enough) 😭 This is really a question we're dealing with everyday in #rheumatology when taking care of patients with #autoimmune and other rheumatic diseases 👍 https://t.co/osUPYSvuWf
Dr. John Cush RheumNow
3 years ago
Autoimmune Disease Augments Cardiovascular Risk
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
https://t.co/TtiH9ZBkR8 https://t.co/jVZBk8l4XD
A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.
Dr. John Cush RheumNow
3 years ago
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/lSvnAkRvxB https://t.co/i7ZORYyKHP
Donald Thomas, MD lupuscyclopedia
3 years ago
Learn how to manage lupus: 'The Lupus Encyclopedia: A Comprehensive Guide for Patients and Families' - on #BookBuzz - https://t.co/hvnoFRiabA
Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).
As goes SLE, bullous disease typically affects women, especially those of African descent.
Dr. John Cush RheumNow
3 years ago
Chinese study of 215 Bx proven #SLE pts - all rx w/ IV CTX+steroids. Responders were given either AZA or leflunomide. Renal outcomes were same w/ LEF or AZA as maintenance. Flares (16% vs 18%), Time to flare (16 v 14 mos), AE, proteinuria https://t.co/Ad7Ec4OPco https://t.co/NoKAgiMKrK
Dr. John Cush RheumNow
3 years ago
Low Dose IL-2 Therapy in SLE
A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe SLE.
https://t.co/PNOp3Zdc8M https://t.co/B8DmUs5iuH
Dr. John Cush RheumNow
3 years ago
Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage. https://t.co/gbSn0ZcFEK https://t.co/qjOSNvkIPC
Dr. John Cush RheumNow
3 years ago
Worldwide there are 484,213 #SLE cases in 2017 (7MM), with 54% in the USA (259,474 cases), the rest in the EU and Japan. Next most prevalent was UK (62,852) followed by Italy. Spain has lowest prevalence of SLE https://t.co/anRCYwrLoM https://t.co/nHbLzC0mSd
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.
Dr. John Cush RheumNow
3 years ago
Medicare study of 10,868 Hospitalized lupus pts. Looking at age groups. 30 d rehospitalization higher in young adult LE (36%) - 40% higher than those without LE, 85% higher older LE. Rehospitalization higher with Longer hosp stay & higher comorbidity. https://t.co/Ul91DX6H8r https://t.co/t3plpQQ8qn
Dr. John Cush RheumNow
3 years 1 month ago
Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU
A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE). This is not surprising as IL-2 is needed to bolster insufficient regulatory T cell (Treg) activity, thought to be pivotal to the pathophysiology of SLE.
A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs.
Poster Hall